Baxter International slashed its 2025 profit forecast and posted disappointing quarterly earnings on Thursday, as lingering ...

While Baxter International has lagged the broader market over the past year, Wall Street analysts remain cautiously ...

Stifel downgraded Baxter International to ‘Hold’ from ‘Buy’ and slashed the price target to $25 from $36. The analysts ...

Baxter (NYSE:BAX) downgraded to Hold by Stifel after weak Q2 earnings, lowered guidance, and operational challenges. Read ...

Baxter saw its stock price plunge by more than 20% after it lowered its revenue projections for the remainder of this year, ...

Deerfield-based Baxter International is still feeling battered by Hurricane Helene and problems with its Novum infusion pumps ...

Baxter International (BAX) stock was downgraded at Goldman Sachs after the company missed Street forecasts with its Q2 2025 ...

Baxter International cut its 2025 profit forecast on Thursday, while quarterly earnings missed analysts' estimates due to the ...

Baxter International has voluntarily paused shipments and planned installations of its Novum infusion pump. In April, the FDA reported an underinfusion risk with the company’s Novum IQ large-volume ...